ClinicalTrials.Veeva

Menu

Biomarkers Research in Anxiety for Validation and Efficacy (BRAVE)

Boston Children's Hospital logo

Boston Children's Hospital

Status

Enrolling

Conditions

Autism Spectrum Disorder
Autism

Treatments

Behavioral: Being Brave

Study type

Interventional

Funder types

Other

Identifiers

NCT06221176
P00046792

Details and patient eligibility

About

A within-subjects design will be used for this preliminary investigation of four biomarkers across two contexts of use: prediction of treatment response (i.e., stratification) and quantification of response (i.e., change).

Full description

A within-subjects design will be used for this preliminary investigation of four biomarkers across two contexts of use: prediction of treatment response (i.e., stratification) and quantification of response (i.e., change).

The main questions the study aims to answer are:

  • To evaluate the stability of each potential biomarker over a 3-4-week retest period. The biomarkers are hypothesized to have adequate stability (ICC: > .5) in the absence of intervention.
  • To determine which baseline biomarker scores predict response to a manualized cognitive behavioral therapy (CBT) program for treating anxiety, Being Brave.
  • To determine which biomarkers are sensitive to treatment response.

Enrollment

25 estimated patients

Sex

All

Ages

3 to 6 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Age between 3;0 and 6;11 years old
  • A diagnosis of autism spectrum disorder using DSM-5 diagnostic criteria
  • A diagnosis of anxiety disorder using DSM-5 diagnostic criteria
  • Use of fluent 2-3 word phrases or fluent speech (i.e., Module 2 or 3 for ADOS-2)
  • Cognitive ability (either verbal or non-verbal IQ) > 80 using the DAS-2
  • A parent/guardian who is willing/able to participate and respond to interviews/surveys in English and willing/able to participate in Being Brave parent training in English and support homework activities.

Exclusion criteria

  • Presence of seizures
  • Premature birth (<36 weeks) or low birth weight (<2500 gms)
  • Known genetic or medical disorders (e.g., Fragile X), or injuries (e.g., stroke) with implications for the nervous system or that require regular psychoactive medication that alter EEG/RSA/EDR signal (e.g., anti-convulsants)
  • Significant sensory or motor impairment (e.g., blindness)
  • Major physical abnormalities
  • Exposure to environmental factors that could contribute to neurocognitive delays (significant alcohol exposure in utero, extreme environmental deprivation)
  • Previous CBT for anxiety
  • Presence of conduct or oppositional defiant disorder or ADHD so severe as to interfere with the child's ability to take part in treatment
  • Presence of a primary presenting problem for which the intervention would be inappropriate (e.g., obsessive-compulsive disorder, severe mood disorder, suicidality)
  • Psychotic symptoms in the child or parents
  • Parent/caregiver who is not fluent in English or English is spoken in the home less than half of the time.

Trial design

Primary purpose

Screening

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

25 participants in 1 patient group

Intervention Group
Experimental group
Description:
Being Brave
Treatment:
Behavioral: Being Brave

Trial contacts and locations

1

Loading...

Central trial contact

Susan C Faja, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems